Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up to $1.26 billion, to develop, manufacture, and commercialize Hanmi’s promising biologic drug candidate, sonefpeglutide, on a worldwide basis, excluding South Korea. This strategic collaboration underscores Lilly’s continued aggressive expansion in the biopharmaceutical sector and highlights the innovative potential of Hanmi’s proprietary LAPSCOVERY long-acting platform technology.
The agreement centers on sonefpeglutide, a novel therapeutic candidate that leverages Hanmi’s advanced LAPSCOVERY technology. This platform is designed to enhance the pharmacokinetic properties of protein-based drugs, leading to extended duration of action and potentially improved patient convenience and adherence. Sonefpeglutide itself is a long-acting glucagon-like peptide-2 (GLP-2) analogue, a class of drugs known for their significant impact on gastrointestinal health. The GLP-2 pathway plays a crucial role in promoting intestinal growth, reducing inflammation, and facilitating the regeneration of intestinal mucosa, making it a promising target for a range of gastrointestinal disorders.
This is not the first instance of Hanmi’s LAPSCOVERY platform achieving regulatory validation. The US Food and Drug Administration (FDA) has previously approved a different biologic that was developed using this same innovative technology, signaling its robustness and therapeutic promise. Hanmi Pharm, a company with a strong track record in research and development, is currently advancing five other drug candidates that utilize this platform technology, further demonstrating its commitment to leveraging this proprietary innovation across multiple therapeutic areas.
The Science Behind Sonefpeglutide and GLP-2’s Therapeutic Potential
Hanmi’s research into sonefpeglutide is rooted in a deep understanding of the biological functions of GLP-2. Non-clinical studies have consistently confirmed GLP-2’s capacity to promote significant intestinal growth, exert anti-inflammatory effects within the gut, and stimulate the regeneration of the intestinal lining. These fundamental properties translate into a wide array of potential therapeutic applications. The company has proactively presented the clinical benefits of its LAPSGLP-2 candidates at numerous scientific meetings, building a strong foundation of evidence for the therapeutic efficacy of this drug class.
One of the primary indications for which sonefpeglutide is being developed is short bowel syndrome (SBS). SBS is a debilitating condition characterized by malabsorption of nutrients due to the surgical resection of a significant portion of the small intestine. Patients with SBS often suffer from severe diarrhea, dehydration, malnutrition, and a dependence on parenteral nutrition (intravenous feeding), which carries its own set of complications and significantly impacts quality of life. By promoting intestinal growth and function, GLP-2 analogues like sonefpeglutide hold the potential to reduce reliance on parenteral nutrition, improve nutrient absorption, and ultimately enhance the lives of SBS patients.
A Strategic Partnership with Significant Financial Implications
The financial terms of the agreement highlight the substantial value placed on sonefpeglutide and Hanmi’s underlying technology. Hanmi Pharm is set to receive an upfront payment of $75 million from Eli Lilly and Company. Beyond this initial payment, Hanmi is eligible to earn up to an additional $1.185 billion in milestone payments. These payments are contingent upon the successful achievement of key developmental and commercial benchmarks, including progress in clinical trials, regulatory approvals from global health authorities, and successful market penetration. Furthermore, Hanmi will also be entitled to receive royalties on future product sales once sonefpeglutide is launched commercially, providing a long-term revenue stream.
This structure is typical for significant biopharmaceutical licensing deals, where the upfront payment signifies initial validation and commitment, while the milestone payments incentivize the successful progression of the drug through its development lifecycle. The substantial potential value of the deal underscores Lilly’s confidence in sonefpeglutide’s ability to become a commercially successful therapeutic.
Hanmi’s Ongoing Clinical Development and Lilly’s Strategic Oversight
Under the terms of the agreement, Hanmi Pharm will continue to oversee and manage its ongoing global Phase II clinical trial for sonefpeglutide in short bowel syndrome until its completion. This ensures continuity and leverages Hanmi’s existing expertise in conducting trials for this specific indication. Following the completion of Hanmi’s current trial, Eli Lilly will assume responsibility for the further clinical development of sonefpeglutide, building upon the data generated thus far. This phased approach allows both companies to leverage their respective strengths and expertise.
Eli Lilly will gain exclusive worldwide rights to develop, manufacture, and commercialize sonefpeglutide, with the exception of South Korea, where Hanmi will retain its rights. This global reach for Lilly signifies its intent to position sonefpeglutide as a major treatment option for gastrointestinal disorders in key markets worldwide.
Industry Reactions and Broader Implications
The announcement has been met with significant optimism within the pharmaceutical and biotechnology sectors. Juhyun Lim, Vice-Chairman of Hanmi Pharm, expressed his enthusiasm, stating, "It is highly meaningful that Lilly, one of the most closely watched innovators globally, has highly recognized the development potential for sonefpeglutide." This statement reflects the strategic importance of the partnership for Hanmi, not only financially but also in terms of gaining access to Lilly’s extensive global development, manufacturing, and commercialization capabilities.
For Eli Lilly, this acquisition aligns with its overarching strategy of expanding its therapeutic portfolio through strategic partnerships and acquisitions. The company has been actively pursuing deals to bolster its presence in key therapeutic areas, including oncology, immunology, and diabetes. Earlier in 2026, Lilly announced its intent to acquire three vaccine-specialist biotech companies in a deal valued at $3.8 billion, further demonstrating its commitment to growth through inorganic means and strengthening its infectious disease portfolio. The addition of sonefpeglutide to Lilly’s pipeline strengthens its position in the gastroenterology market, a segment with significant unmet medical needs and substantial commercial potential.
Hanmi Pharm, meanwhile, continues its strategic focus on forging global partnerships and advancing its platform-based research. The company’s commitment to international collaborations is evident in its ongoing R&D efforts in oncology, rare diseases, and obesity/metabolism. This deal with Lilly is a testament to Hanmi’s success in developing innovative platform technologies and translating them into promising drug candidates with significant global commercial potential.
The implications of this agreement extend beyond the immediate financial and strategic benefits for both companies. It highlights the growing importance of platform technologies in drug discovery and development. Hanmi’s LAPSCOVERY platform, with its proven ability to enhance drug properties, serves as a compelling example of how innovative technological approaches can unlock new therapeutic opportunities. Furthermore, the deal underscores the increasing trend of large pharmaceutical companies partnering with smaller, more agile biotech firms to access cutting-edge science and accelerate the development of novel medicines. This symbiotic relationship allows smaller companies to benefit from the resources and expertise of larger players, while larger companies can expand their pipelines and address unmet medical needs more efficiently.
The successful development and commercialization of sonefpeglutide could significantly impact the treatment landscape for short bowel syndrome and potentially other gastrointestinal conditions. By offering a more convenient and effective therapeutic option, it could improve patient outcomes, reduce healthcare burdens, and enhance the overall quality of life for individuals suffering from these debilitating diseases. The ongoing clinical trials will be closely watched by the medical community, investors, and patient advocacy groups alike, as they hold the promise of a new era in the management of gastrointestinal disorders.
Leave a Reply